Gain Therapeutics (GANX) Liabilities and Shareholders Equity (2020 - 2026)

Gain Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 61.2% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $62.4 million (up 8.82% YoY), while the FY2025 annual figure was $22.8 million, up 88.22% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $18.7 million, down from $22.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $37.6 million in Q1 2022, with the low at $9.8 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $18.6 million (2023), against an average of $19.3 million.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity plunged 50.23% in 2023, then surged 88.22% in 2025.
• Gain Therapeutics' Liabilities and Shareholders Equity stood at $24.1 million in 2022, then declined by 22.78% to $18.6 million in 2023, then slumped by 34.85% to $12.1 million in 2024, then soared by 88.22% to $22.8 million in 2025, then decreased by 17.88% to $18.7 million in 2026.
• Business Quant data shows GANX's Liabilities and Shareholders Equity at $18.7 million in Q1 2026, $22.8 million in Q4 2025, and $11.0 million in Q3 2025.